Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida

Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data

Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to generate additional data on the use of nsPFA energy in benign thyroid nodule treatment.

Under the commercial component of the partnership, the Clayman Thyroid Center is now treating patients with the Vybrance System as part of the controlled market development strategy. The center is the only site in the Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules.